New Risk • Jun 12
New major risk - Revenue and earnings growth Earnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. New Risk • Jun 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Large one-off items impacting financial results. New Risk • Mar 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Large one-off items impacting financial results. Announcement • Mar 31
Chengdu Olymvax Biopharmaceuticals Inc., Annual General Meeting, Apr 20, 2026 Chengdu Olymvax Biopharmaceuticals Inc., Annual General Meeting, Apr 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chengdu, Sichuan China Announcement • Mar 30
Chengdu Olymvax Biopharmaceuticals Inc. to Report Q1, 2026 Results on Apr 30, 2026 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report Q1, 2026 results on Apr 30, 2026 Reported Earnings • Mar 05
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: EPS: CN¥0.055 (up from CN¥0.051 in FY 2024). Revenue: CN¥704.2m (up 20% from FY 2024). Net income: CN¥22.2m (up 7.1% from FY 2024). Profit margin: 3.2% (down from 3.5% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) missed analyst estimates by 48%. Revenue is forecast to grow 8.9% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Announcement • Dec 26
Chengdu Olymvax Biopharmaceuticals Inc. to Report Fiscal Year 2025 Results on Mar 20, 2026 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report fiscal year 2025 results on Mar 20, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.084 (vs CN¥0.078 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.084 (up from CN¥0.078 in 3Q 2024). Revenue: CN¥201.1m (up 25% from 3Q 2024). Net income: CN¥34.3m (up 7.2% from 3Q 2024). Profit margin: 17% (down from 20% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 30
Chengdu Olymvax Biopharmaceuticals Inc. to Report Q3, 2025 Results on Oct 30, 2025 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report Q3, 2025 results on Oct 30, 2025 New Risk • Sep 13
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 35% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Large one-off items impacting financial results. Announcement • Jun 30
Chengdu Olymvax Biopharmaceuticals Inc. to Report First Half, 2025 Results on Aug 29, 2025 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report first half, 2025 results on Aug 29, 2025 New Risk • May 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Large one-off items impacting financial results. New Risk • May 06
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 28
First quarter 2025 earnings released: CN¥0.017 loss per share (vs CN¥0.064 loss in 1Q 2024) First quarter 2025 results: CN¥0.017 loss per share (improved from CN¥0.064 loss in 1Q 2024). Revenue: CN¥87.5m (up 24% from 1Q 2024). Net loss: CN¥7.07m (loss narrowed 73% from 1Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 2 years, compared to a 28% growth forecast for the Biotechs industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change). Announcement • Mar 29
Chengdu Olymvax Biopharmaceuticals Inc., Annual General Meeting, Apr 18, 2025 Chengdu Olymvax Biopharmaceuticals Inc., Annual General Meeting, Apr 18, 2025, at 13:00 China Standard Time. Location: The Company's Meeting Room, Chengdu, Sichuan China Announcement • Mar 28
Chengdu Olymvax Biopharmaceuticals Inc. to Report Q1, 2025 Results on Apr 26, 2025 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report Q1, 2025 results on Apr 26, 2025 Reported Earnings • Mar 02
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: EPS: CN¥0.048 (up from CN¥0.043 in FY 2023). Revenue: CN¥588.9m (up 19% from FY 2023). Net income: CN¥19.6m (up 12% from FY 2023). Profit margin: 3.3% (down from 3.5% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.7%. Earnings per share (EPS) missed analyst estimates by 31%. Revenue is forecast to grow 8.9% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. Announcement • Dec 27
Chengdu Olymvax Biopharmaceuticals Inc. to Report Fiscal Year 2024 Results on Mar 29, 2025 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report fiscal year 2024 results on Mar 29, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.078 (vs CN¥0.004 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.078 (up from CN¥0.004 in 3Q 2023). Revenue: CN¥160.4m (up 35% from 3Q 2023). Net income: CN¥32.0m (up CN¥30.2m from 3Q 2023). Profit margin: 20% (up from 1.5% in 3Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Chengdu Olymvax Biopharmaceuticals Inc. to Report Q3, 2024 Results on Oct 30, 2024 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report Q3, 2024 results on Oct 30, 2024 Announcement • Jun 29
Chengdu Olymvax Biopharmaceuticals Inc. to Report First Half, 2024 Results on Aug 22, 2024 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report first half, 2024 results on Aug 22, 2024 New Risk • May 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 27
First quarter 2024 earnings released: CN¥0.064 loss per share (vs CN¥0.01 profit in 1Q 2023) First quarter 2024 results: CN¥0.064 loss per share (down from CN¥0.01 profit in 1Q 2023). Revenue: CN¥70.8m (up 5.9% from 1Q 2023). Net loss: CN¥26.0m (down CN¥29.9m from profit in 1Q 2023). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China. Announcement • Apr 27
Chengdu Olymvax Biopharmaceuticals Inc., Annual General Meeting, May 17, 2024 Chengdu Olymvax Biopharmaceuticals Inc., Annual General Meeting, May 17, 2024, at 13:00 China Standard Time. Location: The Company's Meeting Room, Chengdu, Sichuan China Announcement • Mar 29
Chengdu Olymvax Biopharmaceuticals Inc. to Report Q1, 2024 Results on Apr 26, 2024 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Feb 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.043 (down from CN¥0.066 in FY 2022). Revenue: CN¥496.1m (down 9.4% from FY 2022). Net income: CN¥17.4m (down 35% from FY 2022). Profit margin: 3.5% (down from 4.9% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 71%. Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. New Risk • Feb 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.2% net profit margin). New Risk • Nov 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.2% net profit margin). Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.004 (vs CN¥0.023 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.004 (down from CN¥0.023 in 3Q 2022). Revenue: CN¥119.1m (down 14% from 3Q 2022). Net income: CN¥1.74m (down 81% from 3Q 2022). Profit margin: 1.5% (down from 6.6% in 3Q 2022). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. New Risk • Oct 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (35% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). Reported Earnings • Aug 18
Second quarter 2023 earnings released: EPS: CN¥0.061 (vs CN¥0.093 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.061 (down from CN¥0.093 in 2Q 2022). Revenue: CN¥166.3m (down 7.2% from 2Q 2022). Net income: CN¥24.7m (down 35% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Announcement • Jun 28
Chengdu Olymvax Biopharmaceuticals Inc. to Report First Half, 2023 Results on Aug 18, 2023 Chengdu Olymvax Biopharmaceuticals Inc. announced that they will report first half, 2023 results on Aug 18, 2023 Reported Earnings • Apr 26
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.066 (down from CN¥0.28 in FY 2021). Revenue: CN¥547.5m (up 12% from FY 2021). Net income: CN¥26.6m (down 75% from FY 2021). Profit margin: 4.9% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.0%. Earnings per share (EPS) also missed analyst estimates by 53%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Reported Earnings • Mar 01
Full year 2022 earnings released: EPS: CN¥0.066 (vs CN¥0.28 in FY 2021) Full year 2022 results: EPS: CN¥0.066 (down from CN¥0.28 in FY 2021). Revenue: CN¥547.5m (up 12% from FY 2021). Net income: CN¥26.6m (down 75% from FY 2021). Profit margin: 4.9% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. 1 independent director (5 non-independent directors). Independent Director Shao Ping He was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 29
Third quarter 2022 earnings released: EPS: CN¥0.023 (vs CN¥0.087 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.023 (down from CN¥0.087 in 3Q 2021). Revenue: CN¥138.1m (up 19% from 3Q 2021). Net income: CN¥9.13m (down 74% from 3Q 2021). Profit margin: 6.6% (down from 31% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Reported Earnings • Aug 18
Second quarter 2022 earnings released: EPS: CN¥0.093 (vs CN¥0.06 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.093 (up from CN¥0.06 in 2Q 2021). Revenue: CN¥179.2m (up 70% from 2Q 2021). Net income: CN¥37.8m (up 73% from 2Q 2021). Profit margin: 21% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 38%, compared to a 34% growth forecast for the Biotechs industry in China. Reported Earnings • Apr 29
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥0.28 (up from CN¥0.099 in FY 2020). Revenue: CN¥487.2m (up 52% from FY 2020). Net income: CN¥108.0m (up 199% from FY 2020). Profit margin: 22% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 9.5%. Over the next year, revenue is forecast to grow 63%, compared to a 47% growth forecast for the pharmaceuticals industry in China. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Shao Ping He was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 24
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥0.29 (up from CN¥0.099 in FY 2020). Revenue: CN¥487.3m (up 52% from FY 2020). Net income: CN¥110.6m (up 206% from FY 2020). Profit margin: 23% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 63%, compared to a 40% growth forecast for the pharmaceuticals industry in China.